KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Liabilities: 2011-2025

Historic Total Liabilities for Travere Therapeutics (TVTX) over the last 14 years, with Sep 2025 value amounting to $465.0 million.

  • Travere Therapeutics' Total Liabilities fell 13.06% to $465.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $465.0 million, marking a year-over-year decrease of 13.06%. This contributed to the annual value of $535.0 million for FY2024, which is 9.02% down from last year.
  • Latest data reveals that Travere Therapeutics reported Total Liabilities of $465.0 million as of Q3 2025, which was down 11.01% from $522.6 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Total Liabilities registered a high of $629.7 million during Q4 2022, and its lowest value of $401.4 million during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $536.0 million (2024), whereas its average is $552.6 million.
  • As far as peak fluctuations go, Travere Therapeutics' Total Liabilities surged by 54.54% in 2022, and later decreased by 13.54% in 2024.
  • Over the past 5 years, Travere Therapeutics' Total Liabilities (Quarterly) stood at $474.5 million in 2021, then surged by 32.71% to $629.7 million in 2022, then fell by 6.61% to $588.1 million in 2023, then dropped by 9.02% to $535.0 million in 2024, then decreased by 13.06% to $465.0 million in 2025.
  • Its Total Liabilities was $465.0 million in Q3 2025, compared to $522.6 million in Q2 2025 and $516.0 million in Q1 2025.